 |
Current status and prospect of breast cancer treatment |
|
Xu Binghe
(Department of Medical Oncology, Cancer Hospital & Institute, CAMS & PUMC, Beijing 100021, China) |
|
New advances in treatment of operable breast cancer |
|
Xu Binghe Sun Yan
(Department of Medical Oncology, Cancer Hospital & Institute, CAMS & PUMC, Beijing 100021, China) |
|
Pemetrexed: A promising new agent for the treatment of breast cancer |
|
Yuan Peng Xu Binghe
(Cancer Institute & Hospital, CAMS & PUMC, Beijing 100021, China) |
|
Docetaxel and capecitabine combination regimen in treatment of anthracycline-resistant breast cancer |
|
Xu Binghe Zhao Longmei Yuan Peng Chu Datong
(Cancer Institute & Hospital, CAMS & PUMC, Beijing 100021, China) |
|
EIC and the risk of local recurrence after breast-conserving therapy on breast cancer |
|
Liu Deshun Sun Qiang
(PUMC Hospital, CAMS & PUMC, Beijing 100730, China) |
|
Advances in oncoproteomics |
|
Li Yunfeng Fang Fude
(National Laboratory of Medical Biology, Basic Medicine Research of CAMS & PUMC, Beijing 100005, China) |
|
Resveratrol and its effects on cancer chemoprevention |
|
Cao Yu Han Rui
(Institute of Materia Medica, CAMS & PUMC, Beijing 100050, China) |
|
Advance in etiology of cervical cancer |
|
Zhao Fanghui Qiao Youlin
(Department of Epidemiology, Cancer Hospital & Institute, CAMS & PUMC, Beijing 100021, China) |
|
Immunotherapy for ovarian cancer |
|
Zhong Sen
(Department of Obstetrics and Gynecology, PUMC Hospital, CAMS & PUMC, Beijing 100730, China) |
|
Skin manifestations of internal malignancy |
|
Li Li Wang Baoxi
(Dermatology department, PUMC Hospital, CAMS & PUMC, Beijing 100730, China) |
|
Advances of tumor marker radioimmunoassay |
|
Chen Zhizhou Fan Feizhou Fan Zhenfu
(Cancer Institute & Hospital, CAMS & PUMC, Beijing 100021) |
|
Meningeal metastases |
|
Wang Huijie Zhang Xiangru
(Department of Medicine, Cancer Hospital, CAMS & PUMC, Beijing 100021, China) |
|
EGFR for cancer treatment |
|
Shen Wenjiang
(Rodiotherepy Dept, 1st Hospital of Beijing University) |
